ArticleEuropean heart journal2019
Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention?
Article in European heart journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Combination of antiplatelet and anticoagulant therapy, component network meta-analysis of randomized controlled trials.Frontiers in cardiovascular medicine · 2022Pooled it
- Stroke of antiplatelet and anticoagulant therapy in patients with coronary artery disease: a meta-analysis of randomized controlled trials.BMC cardiovascular disorders · 2021Pooled it
- P2YReviews in cardiovascular medicine · 2025Article
- Long-Term Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention.Journal of clinical medicine · 2025Review
- AZALEA-TIMI 71 trial: less bleeding with abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain.European heart journal. Cardiovascular pharmacotherapy · 2025Article
- OCEANIC-AF trial: factor XI inhibitors revolution in atrial fibrillation is on hold.European heart journal. Cardiovascular pharmacotherapy · 2024Article
- Ticagrelor monotherapy after acute coronary syndrome: lessons from the ULTIMATE-DAPT trial.Future cardiology · 2024Article
- Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.Journal of clinical medicine · 2023Review
- Serum fibrinogen-to-albumin ratio predicts new-onset atrial fibrillation risk during hospitalization in patients with acute myocardial infarction after percutaneous coronary intervention: a retrospective study.BMC cardiovascular disorders · 2023Article
- Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials.Medicina (Kaunas, Lithuania) · 2023Article
- Choice of antithrombotic therapy for patients with atrial fibrillation undergoing carotid angioplasty and stenting: a nationwide population-based study.Scientific reports · 2022Article
- First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects.Frontiers in pharmacology · 2022Article
- Non-invasive skin cholesterol testing: a potential proxy for LDL-C and apoB serum measurements.Lipids in health and disease · 2021Article
- Characteristics and antithrombotic treatment patterns of patients with concomitant coronary artery disease and atrial fibrillation from Thailand's COOL-AF registry.BMC cardiovascular disorders · 2021Article
- Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry.Internal and emergency medicine · 2021Article
- Effectiveness and safety of antithrombotic strategies in elderly patients with acute myocardial infarction.World journal of cardiology · 2020Article
- No free lunch-the price of double versus triple antithrombotic therapy in patients with atrial fibrillation after ACS or PCI.Annals of translational medicine · 2020Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
30395219What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.